Early detection of pancreatic carcinoma

Hematol Oncol Clin North Am. 2002 Feb;16(1):37-52. doi: 10.1016/s0889-8588(01)00007-7.

Abstract

The poor prognosis and late presentation of pancreatic cancer patients emphasize the importance of an effective early detection strategy for patients at risk of developing pancreatic cancer. In current practice, the use of CA 19-9 levels and imaging techniques is not optimal for detecting small pancreatic lesions. It is hoped that the understanding of genetic alterations in combination with the development of high-throughput sensitive techniques will lead to the rapid discovery of a panel of biomarkers that will save lives by enabling aggressive therapy at the time when tumors are curable.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Biomarkers, Tumor / blood
  • CA-19-9 Antigen / blood
  • Cell Transformation, Neoplastic / genetics
  • DNA-Binding Proteins
  • Diagnostic Imaging
  • Disease Progression
  • Genes, Tumor Suppressor
  • Humans
  • Hyperplasia
  • Mass Screening
  • Models, Biological
  • Neoplastic Syndromes, Hereditary / genetics
  • Oncogenes
  • Pancreas / pathology
  • Pancreatic Juice / enzymology
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / pathology
  • Proteomics
  • Smoking / adverse effects
  • Telomerase / analysis

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • DNA-Binding Proteins
  • Telomerase